Tower Research Capital (TRC)’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-6,838
| Closed | -$25K | – | 4265 |
|
|
2017
Q4 | $25K | Sell |
6,838
-1,477
| -18% | -$6.05K | ﹤0.01% | 1911 |
|
|
2017
Q3 | $34K | Buy |
+8,315
| New | +$31.8K | ﹤0.01% | 2340 |
|
|
2017
Q2 | – | Sell |
-2,742
| Closed | -$11K | – | 3924 |
|
|
2017
Q1 | $11K | Buy |
+2,742
| New | +$11.5K | ﹤0.01% | 1737 |
|
|
2016
Q4 | – | Sell |
-8,263
| Closed | -$81K | – | 4818 |
|
|
2016
Q3 | $81K | Buy |
8,263
+341
| +4% | +$2.42K | 0.01% | 904 |
|
|
2016
Q2 | $45K | Buy |
+7,922
| New | +$53.8K | ﹤0.01% | 1642 |
|
|
2016
Q1 | – | Sell |
-710
| Closed | -$9K | – | 5454 |
|
|
2015
Q4 | $9K | Sell |
710
-815
| -53% | -$14K | ﹤0.01% | 2344 |
|
|
2015
Q3 | $25K | Sell |
1,525
-2,082
| -58% | -$42.7K | ﹤0.01% | 1566 |
|
|
2015
Q2 | $81K | Buy |
+3,607
| New | +$57.1K | 0.01% | 1011 |
|
|
2014
Q4 | – | Sell |
-1,366
| Closed | -$15K | – | 5122 |
|
|
2014
Q3 | $15K | Sell |
1,366
-2,862
| -68% | -$43.7K | ﹤0.01% | 2561 |
|
|
2014
Q2 | $82K | Buy |
4,228
+3,557
| +530% | +$62.8K | 0.01% | 1009 |
|
|
2014
Q1 | $12K | Sell |
671
-1,395
| -68% | -$22.9K | ﹤0.01% | 2467 |
|
|
2013
Q4 | $22K | Buy |
2,066
+1,931
| +1,430% | +$21.6K | ﹤0.01% | 2252 |
|
|
2013
Q3 | $2K | Sell |
135
-3,475
| -96% | -$36.6K | ﹤0.01% | 4193 |
|
|
2013
Q2 | $34K | Buy |
+3,610
| New | +$46.4K | ﹤0.01% | 1250 |
|
Tower Research Capital (TRC)'s CASC Position: Q1 2018 in Review
Tower Research Capital (TRC) sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 6,838 shares — an estimated $25K sold.
Tower Research Capital (TRC) first reported a position in CASC in Q2 2013 and held it in 14 quarters. The position peaked at $82K in Q2 2014. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Tower Research Capital (TRC) reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 6,838 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $25K.
- Tower Research Capital (TRC) first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
- Tower Research Capital (TRC)'s Cascadian Therapeutics, Inc. position peaked at $82K in Q2 2014.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2018, filed 15 May 2018.